ACLX Arcellx, Inc.
FY2025 10-K
Arcellx, Inc. (ACLX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biotech developing novel D-Domain powered CAR-T immunotherapies for cancer and autoimmune diseases
- • New emphasis: ARC-SparX universal CAR-T platform and expanded non-oncology trials including Phase 1 generalized Myasthenia Gravis (gMG) dosing in 2025
Risk Factors
- • Regulatory risk: Hart-Scott-Rodino Antitrust Act clearance required for Gilead merger, with timing and approval uncertainty risking deal abandonment
- • Macroeconomic risk: Global pandemics and U.S. trade policy changes may disrupt operations and third-party providers critical to business
Financial SummaryXBRL
Revenue
$22M
Net Income
-$229M
Operating Margin
-1135.6%
Net Margin
-1027.3%
ROE
-56.9%
Total Assets
$604M
EPS (Diluted)
$-4.07
Operating Cash Flow
-$210M
Source: XBRL data from Arcellx, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcellx, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.